Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Resilience Training Intervention: Its Effect on Parental Acceptance/Rejection and Burden of Children With Down Syndrome

NCT07306923 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-12
Last updated
2025-12-29

Condition(s) studied

Down Syndrome

Investigational drug(s) / intervention(s)

resilience training intervention

resilience training intervention: A structured resilience training program delivered to parents of children with Down syndrome. The program consists of sessions designed to improve psychological resilience, enhance parental acceptance, and reduce caregiving burden. Training methods may include group discussions, skill-building exercises, and home practice tasks.

Study summary

This research will test whether a resilience training program can help parents of children with Down syndrome feel more accepting of their child and experience less caregiving burden.

Parents who care for a child with Down syndrome often face stress and emotional challenges. Building psychological resilience-the ability to adapt and recover from stress-may improve how parents cope and relate to their children.

The study will include about 50 parents of children with Down syndrome. Participants will be randomly assigned to one of two groups:

Experimental group: Receives the resilience training program.

Control group: Receives usual care.

Study phases

Before the program: Parents complete questionnaires that measure their resilience, their acceptance or rejection of their child, and their caregiving burden.

During the program: Parents in the experimental group attend a structured resilience training program based on their expressed needs.

After the program: The same questionnaires are repeated immediately after the program and again at a follow-up to see if any changes last.

The research hypothesis is that parents who take part in the resilience training will show higher acceptance, lower rejection, and reduced caregiving burden compared with parents who receive usual care.

This study will provide evidence on whether resilience training is a helpful, practical, and safe way to support families raising a child with Down syndrome.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Biological parent (mother or father) of a child (birth to 3 years old) diagnosed with Down syndrome. * Age 18 years or older. * Able to read and understand the study questionnaires and provide informed consent. * Willing to attend all resilience training sessions (for the experimental group). * parents who are not responsible for caring of any other patients in the family Exclusion Criteria: * Presence of severe mental illness (e.g., psychosis) or cognitive impairment that would hinder participation. * Current enrollment in another structured psychological or parenting program aimed at resilience or acceptance. * Any acute medical condition preventing attendance of the sessions.

Primary outcome measure(s)

  • Parental Acceptance-Rejection scale — Baseline (pre-intervention), immediately post-intervention, and 1-month follow-up
    Mean change in parental acceptance-rejection score of parents of children with Down syndrome, measured using the Parental Acceptance-Rejection Questionnaire (PARQ) at baseline, immediately post-intervention, and 1-month follow-up.

Trial sites (1)

FacilityCityRegionStatus
Medical Research Centre of Excellence which is affiliated to National Research Centre (NRC). Cairo Cairo Governorate
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07306923 on ClinicalTrials.gov ↗ ← All trials in Egypt